Form 4: 180 Life Sciences CEO Jordan Blair Acquires Voting Rights for Significant Share Block
SEC Form 4
CEO Jordan Blair gains voting control over 243,166 shares of 180 Life Sciences Corp. through voting agreements with shareholders.
Summary
- On February 21, 2025, Jordan Blair, CEO of 180 Life Sciences Corp., filed a Form 4 indicating changes in beneficial ownership.
- The filing reveals that Blair entered into voting agreements with Dr. James Woody and Dr. Marlene Krauss.
- These agreements grant Blair irrevocable voting proxies over 43,166 shares held by Dr. Woody and 200,000 shares held by Dr. Krauss.
- Blair now has voting control over a total of 243,166 shares, in addition to the 160,000 shares he directly owns.
- The voting agreements stipulate that Blair will vote the shares as recommended by the Board of Directors of 180 Life Sciences Corp.
- The agreement with Dr. Woody is valid until February 5, 2026, or until Dr. Woody sells all shares, or until the Issuer terminates the Voting Agreement.
- The agreement with Dr. Krauss is valid until August 21, 2025.
- Blair does not have dispositive control or any pecuniary interest in the shares covered by the voting agreements.
Sentiment
Score: 6
Explanation: The document is neutral in tone, simply reporting a change in beneficial ownership. The impact on the company is neither explicitly positive nor negative.
Positives
- The acquisition of voting rights could strengthen the CEO's influence and alignment with the Board's strategic direction.
- Increased voting power may provide stability and confidence to investors.
Risks
- The concentration of voting power in the hands of the CEO could raise concerns about corporate governance if not managed transparently.
- The voting agreements are temporary and will expire, potentially altering the voting landscape.
Industry Context
Changes in beneficial ownership are common in publicly traded companies and are closely monitored by investors for insights into management's confidence and strategic direction.
Stakeholder Impact
- Shareholders may view the increased voting power of the CEO as a sign of stability or potential overreach, depending on their perspective.
- Employees may be indirectly affected by any strategic shifts resulting from the CEO's increased influence.
Key Dates
| Date | Description |
|---|---|
| 02/05/2025 | Date of Voting Agreement between the Issuer, the Reporting Person and Dr. James Woody |
| 02/21/2025 | Date of Transaction and Voting Agreement between the Issuer, the Reporting Person and Dr. Marlene Krauss |
| 04/02/2025 | Date of Signature |
| 08/21/2025 | Expiration date of the Voting Agreement between the Issuer, the Reporting Person and Dr. Marlene Krauss |
| 02/05/2026 | Expiration date of the Voting Agreement between the Issuer, the Reporting Person and Dr. James Woody |
Keywords
voting rights, beneficial ownership, Form 4, Jordan Blair, 180 Life Sciences Corp, voting agreement, proxy
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.